Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition.

Varano G, Raffel S, Sormani M, Zanardi F, Lonardi S, Zasada C, Perucho L, Petrocelli V, Haake A, Lee AK, Bugatti M, Paul U, Van Anken E, Pasqualucci L, Rabadan R, Siebert R, Kempa S, Ponzoni M, Facchetti F, Rajewsky K, Casola S.

Nature. 2017 Jun 8;546(7657):302-306. doi: 10.1038/nature22353. Epub 2017 May 31.

PMID:
28562582
2.

CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.

Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A.

J Clin Invest. 2012 Jun;122(6):2257-66. doi: 10.1172/JCI45851. Epub 2012 May 1.

3.

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM.

Nature. 2010 Jan 7;463(7277):88-92. doi: 10.1038/nature08638.

4.

The class-specific BCR tonic signal modulates lymphomagenesis in a c-myc deregulation transgenic model.

Amin R, Marfak A, Pangault C, Oblet C, Chanut A, Tarte K, Denizot Y, Cogné M.

Oncotarget. 2014 Oct 15;5(19):8995-9006.

5.

B-cell receptor signaling as a driver of lymphoma development and evolution.

Niemann CU, Wiestner A.

Semin Cancer Biol. 2013 Dec;23(6):410-21. doi: 10.1016/j.semcancer.2013.09.001. Epub 2013 Sep 20. Review.

6.

Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells.

He X, Kläsener K, Iype JM, Becker M, Maity PC, Cavallari M, Nielsen PJ, Yang J, Reth M.

EMBO J. 2018 Jun 1;37(11). pii: e97980. doi: 10.15252/embj.201797980. Epub 2018 Apr 18.

7.

MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.

Wang WG, Jiang XN, Liu ZB, Zhou XY, Li XQ.

Am J Surg Pathol. 2017 Apr;41(4):541-549. doi: 10.1097/PAS.0000000000000799.

PMID:
28291124
8.

B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.

Cozma D, Yu D, Hodawadekar S, Azvolinsky A, Grande S, Tobias JW, Metzgar MH, Paterson J, Erikson J, Marafioti T, Monroe JG, Atchison ML, Thomas-Tikhonenko A.

J Clin Invest. 2007 Sep;117(9):2602-10.

9.
10.

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets.

Bouska A, Bi C, Lone W, Zhang W, Kedwaii A, Heavican T, Lachel CM, Yu J, Ferro R, Eldorghamy N, Greiner TC, Vose J, Weisenburger DD, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, Siebert R, Miles RR, Dave S, Reddy A, Delabie J, Staudt LM, Song JY, McKeithan TW, Fu K, Green M, Chan WC, Iqbal J.

Blood. 2017 Oct 19;130(16):1819-1831. doi: 10.1182/blood-2017-02-767335. Epub 2017 Aug 11.

11.

Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.

Vockerodt M, Wei W, Nagy E, Prouzova Z, Schrader A, Kube D, Rowe M, Woodman CB, Murray PG.

J Pathol. 2013 Aug;230(4):399-409. doi: 10.1002/path.4198.

PMID:
23592216
12.

B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.

Seda V, Mraz M.

Eur J Haematol. 2015 Mar;94(3):193-205. doi: 10.1111/ejh.12427. Epub 2014 Sep 13. Review.

PMID:
25080849
13.

Uncoupling between Ig somatic hypermutation and oncogene mutation in mouse lymphoma.

Vincent C, Truffinet V, Fiancette R, Petit B, Cogné N, Cogné M, Denizot Y.

Biochim Biophys Acta. 2009 Feb;1793(2):418-26. doi: 10.1016/j.bbamcr.2008.10.011. Epub 2008 Nov 3.

14.

Targeting B cell receptor signalling in cancer: preclinical and clinical advances.

Burger JA, Wiestner A.

Nat Rev Cancer. 2018 Mar;18(3):148-167. doi: 10.1038/nrc.2017.121. Epub 2018 Jan 19. Review.

PMID:
29348577
15.

The p54 cleaved form of the tyrosine kinase Lyn generated by caspases during BCR-induced cell death in B lymphoma acts as a negative regulator of apoptosis.

Luciano F, Herrant M, Jacquel A, Ricci JE, Auberger P.

FASEB J. 2003 Apr;17(6):711-3. Epub 2003 Feb 5.

PMID:
12586738
16.

MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma.

Wang WG, Liu ZB, Jiang XN, Lee J, Zhou XY, Li XQ.

Histopathology. 2017 Nov;71(5):778-785. doi: 10.1111/his.13287. Epub 2017 Sep 15.

PMID:
28639315
17.
18.

Identification of a new gene regulatory circuit involving B cell receptor activated signaling using a combined analysis of experimental, clinical and global gene expression data.

Schrader A, Meyer K, Walther N, Stolz A, Feist M, Hand E, von Bonin F, Evers M, Kohler C, Shirneshan K, Vockerodt M, Klapper W, Szczepanowski M, Murray PG, Bastians H, Trümper L, Spang R, Kube D.

Oncotarget. 2016 Jul 26;7(30):47061-47081. doi: 10.18632/oncotarget.9219.

19.

Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.

Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, Tae Chung S, Torrey TA, Cheung WC, Polakiewicz RD, McNeil N, Ried T, Mushinski JF, Morse HC 3rd, Janz S.

Cancer Res. 2005 Feb 15;65(4):1306-15.

20.

Myc suppression of Nfkb2 accelerates lymphomagenesis.

Keller U, Huber J, Nilsson JA, Fallahi M, Hall MA, Peschel C, Cleveland JL.

BMC Cancer. 2010 Jul 2;10:348. doi: 10.1186/1471-2407-10-348.

Supplemental Content

Support Center